An advisory panel for the Food and Drug Administration (FDA) recommended on Friday that the agency ease access to six out of seven specific peptides. The Pharmacy Compounding Advisory Committee held a two-day meeting to vote on whether these substances should be added to a list that allows them to be blended by compounding pharmacies.
The meeting followed public statements by Health and Human Services Secretary Robert F. Kennedy Jr., who has expressed support for peptides and indicated a desire to roll back restrictions implemented during the Biden administration. Peptides are strings of amino acids that have gained popularity in the wellness industry, though their regulatory status has been a subject of debate between government scientists and industry proponents.
During the proceedings, the panel’s recommendations were met with opposition from career FDA scientists. These agency officials argued that there is insufficient clinical data to demonstrate that these specific peptides are safe or effective for human use. Rita Jew, president of the Institute for Safe Medication Practices, stated that the lack of evidence is concerning for substances that are frequently administered via injection.
The 20-member panel included several doctors and pharmacists with reported financial ties to the peptide industry, including owners of wellness clinics and compounding pharmacies. To address concerns regarding potential conflicts of interest, the FDA added several academic experts without industry connections to the committee earlier in the week. The committee's votes are non-binding, meaning the FDA is not legally required to follow their recommendations.
The decision affects a growing market involving thousands of compounding pharmacies, wellness influencers, and specialized medical providers. Observers note that this sets a potential precedent for how the Department of Health and Human Services will manage substances popularized in the fitness and "biohacking" communities. If the FDA declines the recommendation, it would maintain existing restrictions, keeping these substances off the official list of bulk drug substances allowed for compounding.
The final decision now rests with leadership at the FDA. The agency will review the panel's non-binding votes alongside the testimony from its own scientists before issuing a final rule or guidance. There is no immediate deadline for the FDA to act, but the agency typically responds to advisory committee votes through formal regulatory filings in the months following a public hearing.